Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated May 9, 2017 (9 years ago)

Montelukast Sodium Oral Granules

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications; out of specification results for Sulphoxide Impurity and Total Impurities

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Montelukast Sodium Oral Granules, 4 mg pouch, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 0378-6040-93

Affected NDC 0378-6040-93

Compare with the code on your package — it is the most precise check available.

Drug: Montelukast

Recalling firm
Mylan Pharmaceuticals Inc.
NDC code
0378-6040-93
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0920-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Montelukast recalls

See all
Class II · Moderate risk

Montelukast Sodium Tablets

Presence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-725-10 D-0086-2024
Class II · Moderate risk

Montelukast Sodium Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-9438-3 D-0518-2023

Other recalls by Mylan Pharmaceuticals Inc.

All 2017 recalls
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026